It has been validated as a prognostic tool in the ABCG-8 and TransATAC trials, in patients treated with endocrine therapy, with ER-positive and node-negative disease, although prospective data on its predictive value are needed, which will be generated in the OPTIMA study in node-positive early breast cancer [51]. Here, ESR1 is linked to breast cancer.